Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling PathwaysYusuke Tomita, Isao Date, Toshihiko Shimizu et al.|Molecular Cancer Therapeutics|2019Cited by 35
Data from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling PathwaysYusuke Tomita, Isao Date, Kazuhiko Kurozumi et al.|Unknown|2023Cited by 0
Supplementary Figure 3 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling PathwaysYusuke Tomita, Isao Date, Ji Young Yoo et al.|Unknown|2023Cited by 0
Supplementary Figure 2 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling PathwaysYusuke Tomita, Isao Date, Kazuhiko Kurozumi et al.|Unknown|2023Cited by 0
Supplementary Figure 2 from Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling PathwaysYusuke Tomita, Isao Date, Kazuhiko Kurozumi et al.|Unknown|2023Cited by 0